2.89

3.58% 0.10

Insight Molecular Diagnostics Inc (IMDX)

Overview News Price History Option Chain Financials Discussions Forecast

Insight Molecular Diagnostics Inc stock is traded at $2.89, with a volume of 65,330. It is up +3.58% in the last 24 hours and down -28.11% over the past month. Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Previous Close:

$2.79

Open:

$2.81

24h Volume:

65,330

Relative Volume:

0.21

Market Cap:

$94.57M

Revenue:

$1.95M

Net Income/Loss:

$-47.84M

P/E Ratio:

-1.9485

EPS:

-1.4832

Net Cash Flow:

$-27.46M

1W Performance:

-11.89%

1M Performance:

-28.11%

6M Performance:

-15.50%

1Y Performance:

-32.79%

1-Day Range:

$2.79

$2.98

1-Week Range:

$2.75

$3.441

52-Week Range:

$2.42

$8.51

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name

Insight Molecular Diagnostics Inc

Sector

Healthcare (1051)

Industry

Diagnostics & Research (44)

Phone

949-409-7600

Address

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Employee

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

IMDX's Discussions on Twitter

Compare IMDX vs TMO, DHR, NTRA, A, IQV

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMDX Insight Molecular Diagnostics Inc	2.89	94.57M	1.95M	-47.84M	-27.46M	-1.4832
TMO Thermo Fisher Scientific Inc	693.47	256.41B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	231.63	162.83B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	402.14	57.97B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	176.41	49.74B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	269.58	44.37B	16.63B	1.39B	2.12B	8.0674

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-25	Initiated	Lake Street	Buy
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

Insight Molecular Diagnostics Inc Stock (IMDX) Latest News

Oct 11, 2026

IMDX : Insight Molecular Diagnostics Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research

Oct 11, 2026

May 04, 2017

Retractable Technologies, Inc. (RVP) Stock Price, News, Quote & History - Yahoo! Finance Canada

May 04, 2017

Sep 21, 2026

Insight Molecular (IMDX) shifts Chronix earnout to CNI Monitor test - Stock Titan

Sep 21, 2026

Sep 16, 2026

Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook - Stock Titan

Sep 16, 2026

Sep 11, 2026

Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com

Sep 11, 2026

Sep 04, 2026

Medicare policy boosts iMDx transplant testing frequency - scanx.trade

Sep 04, 2026